ArticleHepatology international2023
Fibro-Scope V1.0.1: an artificial intelligence/neural network system for staging of nonalcoholic steatohepatitis.
Article in Hepatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan.Journal of gastroenterology · 2026Review
- Artificial Intelligence for Fibrosis Diagnosis in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFibro-Scope is an artificial intelligence/neural network system to determine the fibrosis stage in nonalcoholic steatohepatitis (NASH) using 12 parameters of the patient: age, sex, height, weight, waist circumference (WC), platelet count, and the levels of aspartate and alanine aminotransferase, gamma-glutamyltransferase, cholesterol, triglycerides, and type IV collagen 7S. However, measurement of WC is unstable and often missing from patient databases. Herein, we created Fibro-Scope V1.0.1 that has the same detection power as its predecessor, without the need to consider WC.
methodsTo build a new AI diagnostic system available for the global needs, data from 764 patients with NASH and bridging fibrosis (STELLAR-3) or compensated cirrhosis (STELLAR-4) that participated in two phase III trials were added to the Japanese data. Finally, the data of a total of 898 patients in the training and of 300 patients in the validation studies were analyzed, respectively.
resultsThe discrimination of F0-2 from F3,4 through Fibro-Scope V1.0.1 was characterized by a 99.8% sensitivity, a 99.6% specificity, a 99.8% positive predictive value, and a 99.6% negative predictive value in a training study with gray zone analysis; similar effectiveness was also revealed in the analysis without a gray zone. In the validation studies with and without gray zone analysis, high sensitivity and specificity were also identified. Fibro-Scope V1.0.1 exerted a diagnostic accuracy for F3,4 advanced fibrosis that was comparable to that of the original Fibro-Scope and delivered high (> 92%) sensitivity and specificity.
conclusionFibro-Scope V1.0.1 can accurately diagnose F3,4 fibrosis without the need of WC.
Indexed as
Identifiers
36542263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.